The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | Characterization of the tumor microenvironment of patients with post-transplant LBCL
Sirpa Leppa, MD, PhD, University of Helsinki and Helsinki University Hospital, Helsinki, Finland, briefly describes a study investigating the tumor microenvironment in patients with post-transplant large B-cell lymphoma (LBCL) using NanoString and CIBERSORT RNA profiling. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Disclosures
Orion Pharma: Consultancy; Pfizer: Consultancy; Beigene: Consultancy; Genmab: Research Funding; BMS: Consultancy, Research Funding; Bayer: Research Funding; Gilead Sciences: Consultancy, Honoraria; Roche: Consultancy, Research Funding; Novartis: Consultancy, Honoraria, Research Funding; Nordic Nanovector: Research Funding; Incyte: Consultancy, Honoraria.
